Heron Therapeutics Statistics
Total Valuation
HRTX has a market cap or net worth of $201.70 million. The enterprise value is $286.65 million.
Important Dates
The last earnings date was Tuesday, November 4, 2025, before market open.
| Earnings Date | Nov 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
HRTX has 183.36 million shares outstanding. The number of shares has increased by 3.91% in one year.
| Current Share Class | 183.36M |
| Shares Outstanding | 183.36M |
| Shares Change (YoY) | +3.91% |
| Shares Change (QoQ) | +10.60% |
| Owned by Insiders (%) | 0.79% |
| Owned by Institutions (%) | 57.64% |
| Float | 151.86M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 20.95 |
| PS Ratio | 1.12 |
| Forward PS | 4.78 |
| PB Ratio | 28.71 |
| P/TBV Ratio | 28.72 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.85 |
| EV / EBITDA | 72.48 |
| EV / EBIT | 179.50 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.56, with a Debt / Equity ratio of 9.44.
| Current Ratio | 2.56 |
| Quick Ratio | 1.52 |
| Debt / Equity | 9.44 |
| Debt / EBITDA | 24.40 |
| Debt / FCF | n/a |
| Interest Coverage | 0.21 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 0.42% |
| Return on Invested Capital (ROIC) | 0.68% |
| Return on Capital Employed (ROCE) | 1.00% |
| Revenue Per Employee | $1.27M |
| Profits Per Employee | -$111,295 |
| Employee Count | 122 |
| Asset Turnover | 0.66 |
| Inventory Turnover | 0.90 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -37.85% in the last 52 weeks. The beta is 1.34, so HRTX's price volatility has been higher than the market average.
| Beta (5Y) | 1.34 |
| 52-Week Price Change | -37.85% |
| 50-Day Moving Average | 1.26 |
| 200-Day Moving Average | 1.79 |
| Relative Strength Index (RSI) | 33.75 |
| Average Volume (20 Days) | 1,902,415 |
Short Selling Information
The latest short interest is 32.90 million, so 17.94% of the outstanding shares have been sold short.
| Short Interest | 32.90M |
| Short Previous Month | 34.38M |
| Short % of Shares Out | 17.94% |
| Short % of Float | 21.66% |
| Short Ratio (days to cover) | 20.91 |
Income Statement
In the last 12 months, HRTX had revenue of $155.10 million and -$13.58 million in losses. Loss per share was -$0.09.
| Revenue | 155.10M |
| Gross Profit | 102.78M |
| Operating Income | 1.60M |
| Pretax Income | -13.58M |
| Net Income | -13.58M |
| EBITDA | 3.96M |
| EBIT | 1.60M |
| Loss Per Share | -$0.09 |
Full Income StatementBalance Sheet
The company has $55.49 million in cash and $140.44 million in debt, giving a net cash position of -$84.96 million or -$0.46 per share.
| Cash & Cash Equivalents | 55.49M |
| Total Debt | 140.44M |
| Net Cash | -84.96M |
| Net Cash Per Share | -$0.46 |
| Equity (Book Value) | 14.89M |
| Book Value Per Share | 0.04 |
| Working Capital | 139.69M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$30.19 million and capital expenditures -$955,000, giving a free cash flow of -$31.14 million.
| Operating Cash Flow | -30.19M |
| Capital Expenditures | -955,000 |
| Free Cash Flow | -31.14M |
| FCF Per Share | -$0.17 |
Full Cash Flow StatementMargins
Gross margin is 66.27%, with operating and profit margins of 1.03% and -8.75%.
| Gross Margin | 66.27% |
| Operating Margin | 1.03% |
| Pretax Margin | -8.75% |
| Profit Margin | -8.75% |
| EBITDA Margin | 2.55% |
| EBIT Margin | 1.03% |
| FCF Margin | n/a |
Dividends & Yields
HRTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.91% |
| Shareholder Yield | -3.91% |
| Earnings Yield | -6.73% |
| FCF Yield | -15.44% |
Analyst Forecast
The average price target for HRTX is $4.50, which is 309.09% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.50 |
| Price Target Difference | 309.09% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 15.19% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 13, 2014. It was a reverse split with a ratio of 1:20.
| Last Split Date | Jan 13, 2014 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
HRTX has an Altman Z-Score of -8.87 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.87 |
| Piotroski F-Score | 5 |
